XTAI
4104
Market cap424mUSD
Oct 08, Last price
72.00TWD
1D
0.00%
1Q
3.15%
Jan 2017
86.63%
IPO
39.40%
Name
Excelsior Medical Co Ltd
Chart & performance
P/E
16.83
P/S
1.54
EPS
4.28
Div yield, %
4.94%
Shrs. gr., 5y
2.92%
Rev. gr., 5y
5.66%
Revenues
8.79b
+2.94%
Net income
806m
+4.49%
CFO
-1.19b
L
Dividend
Apr 23, 20264.3 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Excelsior Medical Co., Ltd. operates as a distributor of a diverse range of healthcare technology and products throughout various Asian nations, specifically Taiwan, mainland China, Japan, South Korea, Malaysia, and the Philippines. Its extensive portfolio encompasses specialized machinery for hemodialysis, routine pharmaceuticals for healthcare facilities, surgical instrumentation, and electronic aids for medical professionals, in addition to cosmetic devices. The company further extends its services to offer administrative support tailored for individual medical departments. Established in 1988, Excelsior Medical maintains its headquarters in New Taipei City, Taiwan.
Key people
Qianhan Li
Deputy General Manager
Yiyan Lu
Deputy General Manager · since 2012
Liqian Yang
Deputy General Manager · since 2010
Chenxiao Zhou
Chief Financial Officer, Deputy General Manager, Corporate Governance Officer · since 2024
Ming-Cheng Chang
General Manager, Director · since 2025
Hsien-Cheng Chang
Director
Qixiu Chen
Vice Chairman of the Board · since 2012
Tun-Ling Chen
Director · since 2001
Director · since 2014
Chairman of the Board · since 2012
Sheng Gao
Vice Chairman of the Board · since 2018
Director · since 2009
Yen-Sheng Hsieh
Director
Qihui Huang
Director
Ming-Ting Wang
Director · since 2023
Junren Zhang
Director · since 2009
Chien-Lung Chan
Independent Director
Chung-Chen Huang
Independent Director · since 2025
Ming-Yi Kuo
Independent Director · since 2025
Zisheng Zhan
Independent Director · since 2008
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||